Working... Menu

Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01906632
Recruitment Status : Recruiting
First Posted : July 24, 2013
Last Update Posted : July 19, 2018
Information provided by (Responsible Party):
Jun Ren MD, PhD, Capital Medical University

Brief Summary:
To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy.

Condition or disease Intervention/treatment Phase
Malignant Tumor Biological: DC-CIK Immunotherapy Not Applicable

Detailed Description:
  1. The patients with malignant tumor are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) .
  2. Venous blood (4 ml) is collected from each subject and placed into tubes containing Ethylene Diamine Tetraacetic Acid(EDTA) before and after each treatment. Lymphocytes are sorted by Fluorescence Activated Cell Sorting(FACS) and stored at -80°C until processing.
  3. The T-Cell Receptor/B-Cell Receptor gene expression is detected by micro-array。
  4. Estimate Immunotherapy response, time to disease progression, survival rates and clinical benefit response on patients. Response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups: sensitive and non-sensitive to immunotherapy.
  5. Compare the gene expression profile between different immunotherapy response groups to explore the mechanism that predict the DC-CIK immunotherapy response.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : May 2013
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
gene expression profile Biological: DC-CIK Immunotherapy

Primary Outcome Measures :
  1. T-Cell Receptor/B-Cell Receptor gene expression [ Time Frame: 3 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • histologically confirmed with malignant tumor;
  • Age: 18-80 years;
  • an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
  • At least one measurable lesion according to the RECIST criteria;
  • Adequate bone marrow, cardiac, liver, and renal function;
  • Life expectancy ≥2 months;
  • Not received other anti-tumor treatment
  • Informed consent signed

Exclusion Criteria:

  • previous history of other malignancies;
  • Uncontrolled central nervous system metastases;
  • Serious or uncontrolled concurrent medical illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01906632

Layout table for location contacts
Contact: Jun Ren, MD, PhD 86-10-63926317

Layout table for location information
Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital Recruiting
Beijing, China, 100038
Contact: Jun Ren, MD, PhD    86-10-63926317   
Sponsors and Collaborators
Capital Medical University

Layout table for additonal information
Responsible Party: Jun Ren MD, PhD, Director, Capita Medical University Cancer Center, Capital Medical University Identifier: NCT01906632     History of Changes
Other Study ID Numbers: GIMC
First Posted: July 24, 2013    Key Record Dates
Last Update Posted: July 19, 2018
Last Verified: July 2018

Additional relevant MeSH terms:
Layout table for MeSH terms